肝癌患者介入治疗术后血清SIL—2R监测及意义探讨

Clinical Significance of Mornitoring Serum SIL-2R in Patients with PHC after TACE Therapy

为探讨血清可溶性白介素一2受体（SIL—2R）在原发性肝癌（PHC）患者肝动脉栓塞化疗（transcatheterarterialchemoembolization，TACE）后的临床意义，分别于术后不同时间检测了15例第1次行TACE和6例反复行TACE术的PHC患者血清SIL—2R水平。结果显示第一次行TACE术的PHC患者治疗前血清SIL—2R水平明显高于正常（P<0．01），经TACE治疗后1周SIL一2R开始下降，2周时最低（P<0．01），但4周时又回复至治疗前水平（P＞0．05）；而多次行TACE术的PHC患者经治疗后2周和4周时仍较低（P<0．01）。提示多次TACE术可提高免疫细胞活性；监测血清SIL—2R水平有助于判断TACE疗效和选择合理的化疗药剂量，也有助于预后的估计。

To investigate the clinical significance of serum soluble interleukin-2 receptor (SIL2R ) in patient with primary hepatic carcinoma(PHC) after transcatheter arterial chemoembolization(TACE),the levels of SIL--2R in different time were measured in 15 patients with PHC after only oneTACE therapy and 6 patients after repeated TACE therapy. The results showed that serum SIL--2Rlevel before only one TACE was significantly higher than that in normal control (P<0.05). SerumSIL--2R level began to decrease at week 1 after TACE therapy and reached minimum at week 2 (P<0.01 ),but returned to untreated level at week 4(P>0.05). In contrast,serum SIL--2R level after repeated TACE therapy was gradually reduced at both week 2 and week 4 (P<0.01). Above data suggested that repeated TACE may enhance the activity of immunological cells, and mornitoring serumSIL--2R level is helpful to determine the efficacy of TACE therapy and choose the reasonable drugdosage of chemical therapy. In addition, it may estimate the prognosis of patients with PHC.